October 2, 2017
Patara Pharma announced positive results from its phase II clinical trial of PA101 in idiopathic pulmonary fibrosis (IPF) and chronic cough. The randomized, double-blind, proof of concept study enrolled 24 patients. PA101 demonstrated a reduction in daytime and 24-hour cough frequency following 14 days of treatment. The reduction was supported by positive trends in cough-specific quality of life and cough severity, as assessed by patients in the study. The therapy was well-tolerated, with no significant treatment-related adverse events. The study also evaluated a second cohort of patients with chronic idiopathic cough, a condition unrelated to IPF. While PA101 was well-tolerated in this group, the drug did not provide a treatment benefit, suggesting that PA101’s benefits are disease specific. Patara now plans to move forward with a robust phase IIb study to identify the optimal dose for PA101.
August 14, 2017
FibroGen reported results of a randomized, double-blind, placebo-controlled phase II study and two combination safety sub-studies of pamrevlumab for treatment of idiopathic pulmonary fibrosis (IPF). In the double-blind, placebo-controlled portion of this study, 103 patients were randomized (1:1) to receive either pamrevlumab or placebo for 48 weeks. Pamrevlumab met the primary efficacy endpoint of change of forced vital capacity percent predicted (FVC % predicted), a measure of change in lung volume, from baseline to week 48 of the study. Statistical significance was demonstrated using a linear slope analysis in the intent to treat population. Average decline in FVC % predicted from baseline to week 48 was 2.85 in the pamrevlumab arm as compared to an average decline of 7.17 in the placebo arm, an absolute difference of 4.33. Pamrevlumab-treated patients had an average decrease in FVC of 129ml at week 48 compared to an average decrease of 308ml in patients receiving placebo. Consistent with previous clinical studies, pamrevlumab was well-tolerated in IPF patients. In the double-blind, active-controlled combination sub-studies, 57 patients were randomized to assess the safety of combining pamrevlumab with approved IPF therapies. Thirty-six patients on a stable dose of pirfenidone were randomized 2:1 to also receive pamrevlumab or placebo for 24 weeks. Twenty-one patients on a stable dose of nintedanib were randomized 2:1 to also receive pamrevlumab or placebo for 24 weeks. Pamrevlumab was well tolerated when administered in combination with either pirfenidone or nintedanib. The company anticipates meeting with the U.S. FDA to address the clinical and regulatory path forward for pamrevlumab in this indication.
November 16, 2015
Boehringer Ingelheim Pharmaceuticals
has issued results of three new post-hoc
analyses from the phase III INPULSIS trials of
OFEV (nintedanib) across various patient
populations with idiopathic pulmonary
fibrosis (IPF). All studies were randomized,
double-blind, placebo-controlled trials comparing
OFEV 150mg twice daily to placebo
for 52 weeks. In total, 160 patients (OFEV 98,
placebo 62) were enrolled from U.S. clinical
trial sites, while 901 patients (OFEV 540,
placebo 361) were enrolled in clinical trials
sites outside the U.S. Annual rate of decline
in forced vital capacity (FVC) in U.S. patients
was 94.7mL/year with OFEV and 242.5mL/
year with placebo (difference of 147.8mL/
year [95% CI: 56.1, 239.4]) while in non-U.S.
patients it was 117mL/year with OFEV and
220mL/year with placebo (difference of
103mL/year [95% CI: 66.2, 139.7]). The hazard
ratio for time to first acute exacerbation
was 0.37 (95% CI: 0.06, 2.12) in U.S. patients
and 0.68 (95% CI: 0.41, 1.15) in non-U.S. patients,
both in favor of OFEV. Adverse events
were reported in 100% and 98.4% of U.S.
patients; and 94.6% and 88.1% of non-U.S.
patients in the OFEV and placebo groups,
respectively. The FDA has approved OFEV for
the treatment of IPF.
June 3, 2013
Promedior reported results a phase Ib trial of PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled study enrolled 21 subjects with IPF. Subjects received PRM-151 doses of 1mg/kg, 5mg/kg or 10mg/kg, or placebo, administered intravenously on days 1, 3, 5, 8 and 15. Subjects were followed for 57 days after receiving their first dose. Subjects who received PRM-151 showed a measurable increase in lung function from baseline, as quantified by percent predicted FVC at eight weeks. The percent predicted FVC for patients dosed with PRM-151 showed a mean increase from baseline of 2.4% at eight weeks; in contrast, patients who received placebo had a mean 1.5% decrease from baseline. Percent predicted FVC increased by 10% from baseline in three of the 14 patients receiving PRM-151, and by 5% in three additional patients receiving PRM-151. In addition, the mean total distance walked in the six-minute walk test increased by 8 meters in PRM-151 treated patients and declined by 10.5 meters in placebo patients. The mean DLCO decreased by 1.79% in PRM-151 treated patients and by 2.33% from baseline in placebo patients. All doses of the drug were well tolerated. Promedior plans to initiate clinical development of PRM-151 in myelofibrosis.
May 23, 2011
Promedior reported results from a phase I trial of PRM-151 for idiopathic pulmonary fibrosis (IPF). This randomized double blind, placebo controlled study initially enrolled 26 healthy subjects who received single intravenous doses of PRM-151 from 0.1mg/kg to 20mg/kg. After completion of dosing of the healthy subjects, three subjects with IPF were administered a single dose of 10mg/kg intravenously. Single doses of PRM-151 up to 20mg/kg were safe and well tolerated in both populations. Analysis of efficacy biomarkers comparing the healthy versus IPF subjects showed a 50% reduction of CD45+/collagen-1+ fibrocytes within peripheral blood of all IPF subjects at 24 hours, and fibrocytes remained suppressed for up to 21 days in the majority of subjects. Analysis also indicated that elevated serum IL-6 levels observed at baseline in the IPF subjects decreased up to 50% (P<0.05) when measured 48 hours after PRM-151 dosing.
March 13, 2006
Amarillo Biosciences reported positive interim results of a clinical trial of their orally administered formulation of low-dose interferon alpha (IFNa), for the treatment of idiopathic pulmonary fibrosis (IPF), at the Southern Regional Meeting of the Society for Clinical Investigations in Atlanta. Results to date indicated that low dose IFNa was well tolerated, with no serious adverse events reported. The regimen was shown to stabilize IPF or produced minimally progressive disease in 10 of 12 subjects who received the drugs for at least 12 months; two subjects had experienced disease stabilization of over 24 and 48 months respectively. This ongoing open-label study has enrolled 20 subjects to date, who received 150 u IFNa via oral lozenge thrice daily. Based on these results, the company announced plans to submit a phase II protocol and an Orphan Drug application for the drug to the FDA.
December 5, 2005
Actelion reported negative results of their phase III BUILD-1 trial of Tracleer (bosentan) for the treatment of idiopathic pulmonary fibrosis (IPF). Trial data failed to demonstrate a significant improvement in distance walked in a 6 minute walk exercise test vs. placebo, the trial's primary endpoint. Secondary data were also non-significant, but did yield a positive trend in the combined incidence of death or treatment failure (worsening of pulmonary function tests or acute IPF decompensation) at 12 months (22.5% for bosentan, vs. 36.1% for placebo; p=0.076). This randomized, double-blind, placebo-controlled, multi-center study enrolled 158 patients, who were treated with the drug or placebo for 12 months. Based on these results, the company announced plans to investigate the drug's ability to reduce mortality in an additional trial.
May 9, 2005
InterMune and Shionogi have reported positive interim results of a phase II trial of pirfenidone, for the treatment of idiopathic pulmonary fibrosis. Positive results from the first 9 months were observed in the study's primary efficacy endpoint, with a trend towards improvement in change in lowest oxygen saturation during a 6-minute exercise test in the overall population (p=0.072), and a significant effect in the subset of patients with milder disease (p=0.0305). Significance in several secondary endpoints was also achieved, including change from baseline in vital capacity (p=0.0366), categorical assessment of the proportion of patients who improved, were stable, or declined (p=0.0028), and portion of patients experiencing acute symptom exacerbations requiring hospitalization (0%, vs. 14% for placebo; p=0.0031). One placebo patient died due to symptom exacerbation. The overall positive trend in data and the worsening of symptoms in the placebo group led the trial's independent Data Safety Monitoring Board (DSMB) to halt the trial early after this planned 9-month interim analysis. This randomized, double-blind, placebo-controlled study enrolled 107 subjects in Japan, and was originally scheduled to have a 12 month treatment period. Following these positive results, InterMune announced plans to meet with the FDA to discuss the design of upcoming phase III trials, which are expected in the first half of 2006.